![[Update] Graph AI Nets $13.3 Mn To Accelerate International Expansion](https://inc42.com/cdn-cgi/image/quality=90/https://asset.inc42.com/2026/07/soc-25-1.jpg "[Update] Graph AI Nets $13.3 Mn To Accelerate International Expansion")
Pharmaceutical-sector focused AI startup Graph AI is in talks to raise $14 Mn (about ₹133 Cr) in a Series A funding round, sources told Inc42.
As AI transforms drug discovery and safety landscape, investors are aggressively backing AI-native startups to capitalise on the opportunity the tech provides
The funding round will be led by US-based Insights Partners, and will also see participation from existing investors, including Bessemer Venture Partners.
Pharmaceutical-sector focused AI startup Graph AI
has raised $13.3 Mn (₹127.2 Cr) in its Series A funding round led by Insight Partners, with participation from existing investor Bessemer Venture Partners.
The startup said that the fresh capital will help it accelerate expansion across the US and Europe markets.
“Since leading Graph AI’s seed round, we’ve watched Raghav and the team turn a bold thesis into live enterprise deployments with measurable outcomes… We are thrilled to deepen our partnership alongside Insight Partners as Graph scales globally. This is what AI disrupting a services-heavy industry looks like.” Bessemer Venture Partners’ partner and India COO Nithin Kaimal said.
Since raising its seed round in October 2025, the AI startup said that it has launched two modules to market. One is /intake, which captures and triages incoming adverse-event reports across every channel, and the second is /nucleus, a safety database that automates case processing end to end.
The startup is now planning to launch a third module, /report, for automated aggregate reporting, this month.
The startup claims to have onboarded pharmaceutical and biotech customers across North America and other markets. It also claims to have secured design partnerships for the modules ahead, including signal, which surfaces emerging safety signals and patterns across cases.
Original | July 6 at 17:04 IST
Pharmaceutical-sector focused AI startup Graph AI is in talks to raise $14 Mn (about ₹133 Cr) in a Series A funding round, sources told Inc42.
The funding round will be led by US-based Insights Partners, and will also see participation from existing investors, including Bessemer Venture Partners, the sources added.
However, the discussions are yet to be finalised, and the funding amount could change.
Questions sent to Graph AI, Insight Partners, and Bessemer Venture Partners didn’t elicit any response till the time of publication.
This comes over eight months after the startup raised .
Founded in 2024 by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), Graph AI offers AI-native platform ‘Graph Safety’ to automate adverse drug event (ADE) monitoring, regulatory submissions, and aggregate safety intelligence for the pharmaceutical and biotech industries.
Pharmacovigilance, which is mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report ADE across a drug’s entire lifecycle, from clinical trials to post-market use.
The startup claims its flagship SaaS product Graph Safety, which is built on its graphx platform, unifies source, intake, case processing, aggregate reporting, signal detection, risk management, and regulatory compliance into one connected ecosystem.
The product, which automates individual case safety reports (ICSR), is already live with enterprise customers. Graph AI is currently working on adding advanced capabilities to Graph Safety across the safety value chain.
This comes at a time when AI adoption is transforming the drug discovery and safety landscape. Investors are actively backing AI-native startups as they look to capitalise on the opportunity the technology provides. For instance, AI-powered drug discovery startup Peptris raised ₹70 Cr (about $7.7 Mn) in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest in February this year.
Overall, AI funding is on the rise as its adoption is increasing across sectors. The funding raised by Indian AI startups surged over 4X YoY to $676 Mn during the first six months of 2026.